Skip to content
Jared Holz, Healthcare Equity Strategy at Jefferies, joins Yahoo Finance's Zack Guzman to discuss the COVID-19 vaccine race as trial participants report day-long exhaustion, fever and headaches....
If you are looking for the best ideas for your portfolio you may want to consider some of Rhizome Partners top stock picks. In September 2019, Rhizome Partners had released its Q2 2019 investor letter. In its Q2 2019 investor letter – you can download a copy here – the firm discussed its investment thesis […]...
Well, there is never a “bad time” to go public. Fisker, though, took a different route through a reverse merger with Apollo Global Management-affiliated Spartan Energy Acquisition Corp. (NYSE:SPAQ), bringing another EV player into the market. SPAQ stock spiked as a result of the announcement. And although it has cooled down somewhat, shares are still up almost 36% over the past six months.
Source: Shutterstock The SPAQ/Fisker deal will yield more than $1 billion of gross proceeds that the newly minted enterprise will use to bankroll the development of the all-electric Fisker Ocean through the start of production in 2022. If all goes according to plan, the company will start generating some serious dough from 2023 onward.
Overall, considering the red-hot state of the EV sector, SPAQ is an exciting spec play that is worth your time.InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SPAQ Stock Has a Lot Going for It
Although there...
The first time that I wrote about Inovio Pharmaceuticals (NASDAQ:INO) in Jan. 2020, it traded at just $4.86 per share .INO stock subsequently soared to $27 in July.
Source: Ascannio / Shutterstock.com Afterwards, I said that INO stock could rise to $30, which never happened.
Instead, the stock flopped, and I weighed in again, warning investors to avoid the shares.InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Recently, Inovio reported a higher-than-expected quarterly loss of 83 cents, and there have been more questions than answers about its INO-4800 vaccine. Things got even worse for INO stock after the FDA halted the company’s clinical trials due to the agency’s questions about its vaccine technology.
But I believe that Inovio is a “blood-in-the-street” opportunity that’s facing a temporary hurdle. From its current price of $11.63, I believe that it could refill its gap at $16.96 in the near-term.
The FDA’s Halt Is Only Temporary
Before the halt, Inovio...
Mario Cordero, Executive Director of the Port of Long Beach, joins Yahoo Finance as the new Gerald Desmond bridge gets ready to open....
Thomas Lee wrote in a note that Trump’s positive test is a “positive development” for coronavirus compliance in the U.S. and “good for markets.”...
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose......
